Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) has earned a consensus rating of “Moderate Buy” from the five research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $7.40.

ATNM has been the subject of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Actinium Pharmaceuticals in a research report on Tuesday, March 11th. Stephens reiterated an “overweight” rating and set a $5.00 price objective on shares of Actinium Pharmaceuticals in a research note on Tuesday, November 19th.

Actinium Pharmaceuticals Stock Performance

Shares of Actinium Pharmaceuticals stock opened at $1.30 on Tuesday. The firm has a market cap of $40.55 million, a PE ratio of -0.94 and a beta of 0.10. The firm’s 50-day simple moving average is $1.21 and its 200-day simple moving average is $1.47. Actinium Pharmaceuticals has a 1 year low of $1.03 and a 1 year high of $10.24.

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in shares of Actinium Pharmaceuticals by 3.0% during the 3rd quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock valued at $1,290,000 after buying an additional 19,843 shares during the period. Northern Trust Corp raised its holdings in shares of Actinium Pharmaceuticals by 4.9% during the 4th quarter. Northern Trust Corp now owns 251,930 shares of the company’s stock valued at $317,000 after purchasing an additional 11,812 shares in the last quarter. Los Angeles Capital Management LLC raised its holdings in shares of Actinium Pharmaceuticals by 25.0% during the 4th quarter. Los Angeles Capital Management LLC now owns 213,950 shares of the company’s stock valued at $270,000 after purchasing an additional 42,770 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Actinium Pharmaceuticals by 49.9% in the 4th quarter. Renaissance Technologies LLC now owns 190,400 shares of the company’s stock worth $240,000 after acquiring an additional 63,400 shares during the period. Finally, Squarepoint Ops LLC raised its holdings in Actinium Pharmaceuticals by 25.4% in the 4th quarter. Squarepoint Ops LLC now owns 183,262 shares of the company’s stock worth $231,000 after acquiring an additional 37,159 shares during the period. Institutional investors and hedge funds own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).